MONTREAL, Aug. 3, 2018 /CNW Telbec/ - LGC Capital Ltd. (TSXV: LG) ("LGC" or the "Company") is pleased to announce the appointment of Daniel Lubienietzky as the Company's Vice President of Corporate Development as of August 7, 2018. The foregoing appointment remains subject to any requisite approval of the TSX Venture Exchange.
In his role as LGC's Vice President of Corporate Development, Mr. Lubienietzky will work with the executive team in identifying new business opportunities, assist with the integration of various transactions completed by the Company, and work with the management of the company and its portfolio companies on strategic planning.
Prior to joining LGC, Mr. Lubienietzky held positions of Director of Business Development and Director of Sales Strategy at TerrAscend Corp, the parent company of Solace Health Inc., a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations. Prior to TerrAscend, Mr. Lubienietzky built and managed a technology resourcing business and held positions in capital markets at TD Securities and the Bank of Canada. Mr. Lubienietzky received his Masters of Business Administration at the University of Toronto'sRotman School of Management.
"Daniel is a tremendous addition to our executive team and we are delighted to welcome him to LGC," said John McMullen, CEO of LGC Capital. "He brings with him a depth of experience in business development and operations from inside a licensed producer of cannabis that will help strengthen our strategic management at LGC and our portfolio companies."
"I am very excited to be joining the executive team at LGC Capital," said Daniel Lubienietzky. "LGC, through its portfolio companies, is in the process of building a world-leading, vertically integrated system of interconnected legal cannabis companies that will capture a massive share of the legal global cannabis market."
LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services with an emphasis on significant investments in global medical cannabis sector.
FORWARD-LOOKING STATEMENTS This press release may contain forward-looking statements with respect to LGC Capital Ltd. ("LGC") and Global Canna Labs (GCL), and their respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward- looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of LGC and GCL could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under "Risk Factors and Risk Management" in LGC's Management's Discussion and Analysis for the fiscal year ended September 30, 2017, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor GCL has any obligation to update such statements, except to the extent required by applicable securities laws.
Caution Regarding Press Releases Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE LGC Capital Ltd
For further information: John McMullen, Chief Executive Officer, Tel.: (416) 803-0698, Email: [email protected]; London contact: Anthony Samaha, Chief Financial Officer, Tel.: +44 (0) 20 7440 0640; Investor Relations: Dave Burwell, The Howard Group Inc., Tel.: (403) 221-9015, Toll Free: 1-888-221-0915, Email: [email protected]